TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04448184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: Patients allocated to the prophylactic Tranexamic Acid group will receive a standardized routine oral or intravenous dose of Tranexamic Acid 1 gram three times daily.~Tranexamic Acid will start when Platelet count is less than 50 x 109/L and continue until platelet engraftment. Patients in this group will not receive routine prophylactic platelet transfusions. Subjects unable to swallow oral Tranexamic Acid pills may have the tablets crushed, administered via nasogastric (NG) tube or the medication will be administered intravenously.
Study: NCT04326569

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Blood sample to quantify copeptin
Study: NCT06346756

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment of dental caries.
Description: The researchers used G-aenial Universal Injectable (GCI), G-aenial A'CHORD (GCA), Tetric Prime (TP), and Filtek Ultimate (FU) composites for premolar Class II restorations.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment of dental caries.
Description: The researchers used G-aenial Universal Injectable (GCI), G-aenial A'CHORD (GCA), Tetric Prime (TP), and Filtek Ultimate (FU) composites for premolar Class II restorations.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment of dental caries.
Description: The researchers used G-aenial Universal Injectable (GCI), G-aenial A'CHORD (GCA), Tetric Prime (TP), and Filtek Ultimate (FU) composites for premolar Class II restorations.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment of dental caries.
Description: The researchers used G-aenial Universal Injectable (GCI), G-aenial A'CHORD (GCA), Tetric Prime (TP), and Filtek Ultimate (FU) composites for premolar Class II restorations.
Study: NCT06476743

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sensory Integration Therapy
Description: This group will receive sensory integration therapy for 30 minutes along with routine physical therapy treatment (warm up exercises and Stretching exercises (hamstrings, quadriceps, and calf muscles) for 15 minutes per session for 3 days a week for 8 week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Balance Board Training
Description: This group will receive balance board training for 30 minutes along with routine physical therapy treatment (warm up exercises and Stretching exercises (hamstrings, quadriceps, and calf muscles) for 15 minutes per session for 3 days a week.
Study: NCT06434961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR6508 plus oral placebo tablets
Description: SHR6508 plus oral placebo tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cinacalcet plus intravenous placebo
Description: Cinacalcet plus intravenous placebo
Study: NCT06151249

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Meritup oral solution
Description: chemotherapy + Meritup

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Meritup oral solution
Description: chemotherapy + Meritup
Study: NCT04726839

Intervention type: OTHER
Intervention: Standard of care for stroke management and evaluation of functionnal outcome at 3 months
Description: Additional tubes at inclusion (maximum 13 mL) Collection of the mRS data during a routine visit if planned at 3 months +/-15 days or, if not during a specific research phone call at 3 months
Study: NCT04406129

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FMT capsules
Description: Intervention: FMT capsules containing extensively screened donor stool.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Description: Intervention: Placebo capsules that do not contain donor stool or any active drug.
Study: NCT05883852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel is a taxoid antineoplastic agent used in the treatment of breast cancer

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel is a taxoid antineoplastic agent used in the treatment of breast cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Carboplatin is a DNA synthesis inhibitor which binds to DNA, inhibits replication and transcription and induces cell death.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab is a humanized monoclonal antibody derived from recombinant DNA,

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Trastuzumab is a humanized monoclonal antibody derived from recombinant DNA,

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Pertuzumab is a recombinant humanized monoclonal antibody that specifically binds to the extracellular dimerization domain (subdomain Ⅱ) of epidermal growth factor receptor 2(HER2).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pertuzumab
Description: Pertuzumab is a recombinant humanized monoclonal antibody that specifically binds to the extracellular dimerization domain (subdomain Ⅱ) of epidermal growth factor receptor 2(HER2).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: Epirubicin is an antineoplastic agent derived from doxorubicin.Epirubicin, like doxorubicin, exerts its antitumor effects by interference with the synthesis and function of DNA and is most active during the S phase of the cell cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: An anticancer (antitumor or cytotoxic) chemotherapy drug that is classified as an alkylating agent. Alkylating agents are compounds that prevent the normal connection of the double helix chain by adding an alkyl group to the guanine base of the DNA molecule. It causes breaks in DNA strands, affecting the ability of cancer cells to proliferate.
Study: NCT05303987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol sedation
Description: After induction with sevoflurane then Propofol will be initiated.~If adequate sedation cannot be attained then a ketamine rescue can be given.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine sedation
Description: After induction with sevoflurane then Dexmedetomidine will be given.~If adequate sedation cannot be attained then a ketamine rescue can be given.
Study: NCT04955626

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2
Description: Intramuscular Injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2
Description: Intramuscular Injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2
Description: Intramuscular Injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular Injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2 OMI
Description: Intramuscular Injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2 OMI
Description: Intramuscular Injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Combination BNT162b2 and BNT162b2 OMI
Description: 30-µg (15-µg each) or 60-µg (30-µg each)~Site prepared dosing suspension from 1 vial each of diluted BNT162b2 and BNT162b2 OMI~Intramuscular Injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Combination BNT162b2 and BNT162b2 OMI
Description: 30-µg (15-µg each) or 60-µg (30-µg each)~Site prepared dosing suspension from 1 vial each of diluted BNT162b2 and BNT162b2 OMI~Intramuscular Injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Combination (Bivalent) BNT162b2 and BNT162b2 OMI
Description: 30-µg (15-µg each) or 60-µg (30-µg each)~Preformulated bivalent mixture (no dilution required) presented in a single vial~Intramuscular Injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Combination (Bivalent) BNT162b2 and BNT162b2 OMI
Description: 30-µg (15-µg each) or 60-µg (30-µg each)~Preformulated bivalent mixture (no dilution required) presented in a single vial~Intramuscular Injection
Study: NCT05910775

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pre and Post Treatment Presentations
Description: A short presentation provided to the participants within 72 hours prior to the first treatment of the acute course. The presentation will emphasize the effectiveness of the treatment, and provide notable encouragement and reassurance. The intervention group will additionally receive a follow up session within 24 hours after the first treatment to provide encouragement and reassurance
Study: NCT06497257

Intervention type: OTHER
Intervention: Evaluating wrist flexor and extensor peak torque
Description: Evaluation of wrist flexor and extensor peak torque

Intervention type: OTHER
Intervention: Evaluating wrist flexor and extensor peak torque
Description: Evaluation of wrist flexor and extensor peak torque

Intervention type: OTHER
Intervention: Evaluating functional disability
Description: Evaluation of functional disability

Intervention type: OTHER
Intervention: Evaluating functional disability
Description: Evaluation of functional disability

Intervention type: OTHER
Intervention: Evaluating hand grip strength
Description: Evaluation of hand grip strength

Intervention type: OTHER
Intervention: Evaluating hand grip strength
Description: Evaluation of hand grip strength
Study: NCT05066100

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prenatal Use of Supple Cups
Description: For pregnant women identified with FIRN and providing consent to participate in this study, Supple Cup usage will be initiated at 32 weeks gestation to begin to elongate the nipples in preparation for breastfeeding.
Study: NCT06200688

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEANUT BALL
Description: Experimental Group: Pregnant women who were applied with a peanut ball were informed about the necessary information related to the ball by the midwife with a visual representation of the positions. A total of 5 positions were shown to the pregnant women. Peanut ball was started to be used when the cervical dilation reached 6 cm. Pregnant women in the active phase, the transition phase, and the second stage of labor where the peanut ball was applied were directed to change positions every 30-45 minutes. Importance was given to selecting positions where the pregnant woman felt comfortable.~Control Group: No intervention was made other than routine practices within the clinic for pregnant women. It was generally observed that pregnant women spent the time until delivery lying down and connected to electronic fetal monitoring.
Study: NCT05395624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-OP-801
Description: 18F Hydroxyl Dendrimer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-OP-801
Description: 18F Hydroxyl Dendrimer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-OP-801
Description: 18F Hydroxyl Dendrimer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-OP-801
Description: 18F Hydroxyl Dendrimer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-OP-801
Description: 18F Hydroxyl Dendrimer
Study: NCT06189040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNT162b2 30µg
Description: intramuscular administration of 30µg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNT162b2 30µg
Description: intramuscular administration of 30µg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNT162b2 30µg
Description: intramuscular administration of 30µg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BNT162b2 30µg
Description: intramuscular administration of 30µg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNT162b2 20µg
Description: intramuscular administration of 20µg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNT162b2 6µg
Description: intradermal administration of 6µg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mRNA-1273 100µg
Description: intramuscular administration of 100µg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mRNA-1273 100µg
Description: intramuscular administration of 100µg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mRNA-1273 50µg
Description: intramuscular administration of 50µg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ChAdOx1-S [Recombinant]
Description: intramuscular administration of not less than 2.5 x 10\^8 infectious units
Study: NCT05816421

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: KEEP
Description: The KEEP model focuses on optimizing the role of foster/kin parents as the agents of positive change for children and youth. Parent KEEP groups for children (ages 4-12) and KEEP-Safe groups for teens (ages 13-19) are delivered by two co-group leaders for 16 weeks. Sessions are 90 minutes each week. The same group of 8-10 foster/kin parents attends each week. Each KEEP group follows a manualized curriculum that emphasizes tailoring the content to the unique needs of the parents and youth in the group. The key parenting principles of the model include: (a) reinforce normative and prosocial behavior, (b) incentivize the behavior that parents want to promote, (c) build cooperation, (d) teach new behaviors, (e) use non-harsh effective limit setting, and (f) manage emotions while parenting.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-Affinity KEEP
Description: Non-Affinity KEEP
Study: NCT06381908

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Calorie-restriction with low carbohydrate
Description: Calorie-restriction and low carbohydrate availability

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calorie-restriction with moderate carbohydrate
Description: Calorie-restriction and moderate carbohydrate availability
Study: NCT05104658

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient-targeted rehabilitation offers
Description: In addition to usual rehabilitation services, patients in the intervention arm will receive patient-targeted rehabilitation offers to support the patients' participation and completion of their heart rehabilitation course.
Study: NCT05093452

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Mothers randomized in the intervention group will receive an educational session based on the motivational interviewing (MI) approach with a midwife. The midwife will have first received a standardized 3 days training session on the content and techniques of MI. The MI intervention will be carried out in simple and understandable language in order to allow discussion and questions from parents rather than provide prescriptive and direct information. The intervention will last approximatively 15 to 20 minutes.

Intervention type: OTHER
Group type: OTHER
Intervention: Information flyer
Description: Mothers randomized in the control group will receive a locally information flyer on childhood vaccines without any oral explanation by the midwife.
Study: NCT06573905

Intervention type: OTHER
Intervention: no intervention
Description: no intervention. this is observational study.

Intervention type: OTHER
Intervention: no intervention
Description: no intervention. this is observational study.

Intervention type: OTHER
Intervention: no intervention
Description: no intervention. this is observational study.

Intervention type: OTHER
Intervention: no intervention
Description: no intervention. this is observational study.
Study: NCT05267301

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AlmegaPL (FDA NDIN # 826)
Description: The investigational product iwi/Cholesterol is a commercially available capsule-form herbal (algae) supplement containing Almega®PL, a Nannochloropsis algae-derived extract rich in eicosapentaenoic acid (EPA). EPA is a type of omega-3 essential fatty acid known to play a beneficial role in protection against cardiovascular disease. Iwi/Cholesterol is the only source of long chain omega-3 that does not contain the DHA that is present in other omega-3 sources (fish oil, krill oil, other algal oils). Almega®PL was registered at the Food and Drug Administration (FDA) as a New Dietary Ingredient (NDIN) in 2014.
Study: NCT05341089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3502970
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3502970
Description: Administered orally.
Study: NCT05917093

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culturally tailored HLWD
Description: Participants receive the culturally tailored HLWD intervention for 6 weeks~* Week 0 - Baseline enrollment.~* Weeks 1-6 will consist of 6 separate group sessions. Diabetes self-management topics will be covered by 2 Black HLWD Facilitators. Participants will meet once a week, for a 2½-hour session, in community settings such as a community center, or church.
Study: NCT04934891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ION547
Description: ION547 will be administered by SC injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: ION547-matching placebo will be administered by SC injection.
Study: NCT05652894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HX008
Description: Drug: HX008 200 mg ,Q3W

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Investigator's Choice Chemotherapy
Description: Drug: bevacizumab 5mg/kg given by IV every 14 days. Other Name: Avastin~Drug: cetuximab 400 mg/sqm initial dose, then 250 mg/sqm once weekly thereafter. Other Name: Erbitux~Drug: oxaliplatin 8 5 mg/sqm by IV, day1. Component of mFOLFOX6.~Drug: irinotecan 180 mg/sqm by IV, day1.Component of FOLFORI.~Drug: calcium Folinate 400 mg/sqm by IV, day1.Component of mFOLFOX6 or FOLFORI.~Drug: 5-fluorouracil 400 mg/sqm, day1,followed by 2400 mg/sqm iv infusion over 46\~48 h.Component of mFOLFOX6 or FOLFORI.
Study: NCT05884333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conditioning Chemotherapy
Description: Conditioning: Cyclophosphamide (CY) 50 mg/kg x1 (day -6), Fludarabine (FLU) 30 mg/m2 x5 (days -6 to -2), Thiotepa (THIO) 5 mg/kg x2 (days -5 \& -4), Total Body Irradiation (TBI) 200 cGy x2 (days -2 \& -1). GVHD prophylaxis: Cyclosporine (CSA) 3 mg/kg q12 hours \& Mycophenolate Mofetil (MMF) 15 mg/kg q8 hours (starting IV day -3).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cord blood graft
Description: The double-unit CB graft will be infused on day 0 per standard practice.
Study: NCT06266507

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ergotherapy Based Parent Coaching
Description: Occupational Therapy Based Parent Coaching intervention will last 10 sessions and will be carried out on the online platform. Sessions are planned to last between 45-60 minutes. The interviews to be held during the sessions are considered as the basic principles of parent coaching; It will be carried out in line with the principles of joint planning, observation, implementation, reflection and feedback. This intervention aims to educate mothers on proper feeding strategies for their children and to enable them to carry out these practices independently.

Intervention type: OTHER
Group type: OTHER
Intervention: Informative Brochure Distribution
Description: No active intervention will be applied to mothers in the target group, and an informative brochure about nutritional problems will be distributed.
Study: NCT05762263

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary
Description: Depending on the allocation arm, participants will be advised to follow a particular dietary plan (either flexitarian eating, time-restricted eating or both combined).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary
Description: Depending on the allocation arm, participants will be advised to follow a particular dietary plan (either flexitarian eating, time-restricted eating or both combined).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary
Description: Depending on the allocation arm, participants will be advised to follow a particular dietary plan (either flexitarian eating, time-restricted eating or both combined).
Study: NCT06044740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: After a no-drug control period, subjects will inhale sevoflurane, administered via a breathing circuit and face mask, until a steady-state target end-tidal expired concentration of 0.4% (corresponding to 0.2 Minimum Alveolar Concentration) is reached.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peripheral Nerve Stimulation
Description: Experimental acute pain stimulus will be delivered using a nerve stimulator. These painful shocks will be paired with a fixed number of the experimental cues, in a pattern that appears random to participants.
Study: NCT05220904

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: spectacles
Description: Spectacle is the the most common treatment for refractive errors.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: spectacles
Description: Spectacle is the the most common treatment for refractive errors.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: perceptual learning
Description: Blurred vision from the eyes can be improved by enhancing the brain's visual processing.
Study: NCT05605184

Intervention type: OTHER
Intervention: Survey
Description: Survey
Study: NCT05330143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC22 1mg/kg
Description: ASC22 single-dose of 1mg/kg vials administered subcutaneously once 4 week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC22 2.5mg/kg
Description: ASC22 single-dose of 2.5mg/kg vials administered subcutaneously once 4 week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiretroviral Therapy
Description: standard antiretroviral therapy including Integrase inhibitors (INSTIs)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiretroviral Therapy
Description: standard antiretroviral therapy including Integrase inhibitors (INSTIs)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Antiretroviral Therapy
Description: standard antiretroviral therapy including Integrase inhibitors (INSTIs)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% saline vials administered subcutaneously once 4 week.
Study: NCT04129515

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NovoTTF-200A
Description: •NovoTTF-200A will be applied continuously, with 21 consecutive days defined as a treatment cycle

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NovoTTF-200A
Description: •NovoTTF-200A will be applied continuously, with 21 consecutive days defined as a treatment cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered once every 3 weeks, with 21 consecutive days also defined as a treatment cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered once every 3 weeks, with 21 consecutive days also defined as a treatment cycle